方法：选取2015-01/12在我院接受治疗的糖尿病黄斑水肿患者80例138眼，采用随机数字表法分为联合组40例67眼(雷珠单抗联合激光治疗)，对照组40例71眼(单纯激光治疗)，对比两组患者治疗效果。

结果：治疗后1wk，3、6mo，两组患者的BCVA(LogMAR)、平均黄斑中心凹厚度较治疗前均显著降低，差异有统计学意义(P<0.05)，联合组的BCVA(LogMAR)、CMT值均低于对照组，差异具有统计学意义(P<0.05)； 治疗后1wk，3、6mo，两组患者眼压较治疗前差异无统计学意义(P>0.05)，两组间眼压比较差异无统计学意义(P>0.05)。

结论：雷珠单抗联合激光治疗糖尿病黄斑水肿效果良好，并可以改善患者视力。

METHODS: Totally 80 patients(138 eyes)with diabetic edema who were treated in our hospital from January 2015 to December 2015 were selected, and 40 patients were randomly divided into the combined group(67 eyes in 40 patients, treated by ranibizumab and laser therapy), the control group(71 eyes in 40 cases, laser treatment only). We compared the treatment effect of the two groups and the impact on the patient's vision.

RESULTS: After treated for 1wk, 3mo, and 6mo, the BCVA(LogMAR)and central macular thickness(CMT)values of the patients in the two groups were significantly lower than those before treatment(P<0.05); the BCVA(LogMAR)and CMT values of the combined group were lower than those of the control group, the difference was statistically significant(P<0.05). After treated for 1wk, 3mo, and 6mo, IOP of the two groups was not significantly different compared with before treatment(P>0.05); IOP value of combined group compared with those of the control group, was not significantly different(P>0.05).

CONCLUSION: The combination of ranibizumab and laser treatment for diabetic macular edema can more significantly reduce macular edema, improve visual acuity.